223 related articles for article (PubMed ID: 17172520)
1. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from hospitals in Beijing, China.
Yang XY; Li CR; Lou RH; Wang YM; Zhang WX; Chen HZ; Huang QS; Han YX; Jiang JD; You XF
J Med Microbiol; 2007 Jan; 56(Pt 1):71-76. PubMed ID: 17172520
[TBL] [Abstract][Full Text] [Related]
2. Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.
Kusuma CM; Kokai-Kun JF
Antimicrob Agents Chemother; 2005 Aug; 49(8):3256-63. PubMed ID: 16048934
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of recombinant lysostaphin against Staphylococcus aureus isolates from anterior nares and blood.
von Eiff C; Kokai-Kun JF; Becker K; Peters G
Antimicrob Agents Chemother; 2003 Nov; 47(11):3613-5. PubMed ID: 14576128
[TBL] [Abstract][Full Text] [Related]
4. [Antiseptic effect of compound lysostaphin disinfectant and its preventive effect on infection of artificial dermis after graft on full-thickness skin defect wound in rats].
Jin J; Zhou H; Cui ZC; Wang L; Luo PF; Ji SZ; Hu XY; Ma B; Wang GY; Zhu SH; Xia ZF
Zhonghua Shao Shang Za Zhi; 2018 Apr; 34(4):225-232. PubMed ID: 29690741
[No Abstract] [Full Text] [Related]
5. Antimicrobial activity of daptomycin tested against Staphylococcus aureus with vancomycin MIC of 2 microg/mL isolated in the United States and European hospitals (2006-2008).
Sader HS; Becker HK; Moet GJ; Jones RN
Diagn Microbiol Infect Dis; 2010 Mar; 66(3):329-31. PubMed ID: 20159377
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus.
LaPlante KL
Diagn Microbiol Infect Dis; 2007 Apr; 57(4):413-8. PubMed ID: 17141452
[TBL] [Abstract][Full Text] [Related]
7. Lysostaphin disrupts Staphylococcus aureus and Staphylococcus epidermidis biofilms on artificial surfaces.
Wu JA; Kusuma C; Mond JJ; Kokai-Kun JF
Antimicrob Agents Chemother; 2003 Nov; 47(11):3407-14. PubMed ID: 14576095
[TBL] [Abstract][Full Text] [Related]
8. Development of vancomycin and lysostaphin resistance in a methicillin-resistant Staphylococcus aureus isolate.
Boyle-Vavra S; Carey RB; Daum RS
J Antimicrob Chemother; 2001 Nov; 48(5):617-25. PubMed ID: 11679550
[TBL] [Abstract][Full Text] [Related]
9. Treatment of methicillin-resistant Staphylococcus aureus in neonatal mice: lysostaphin versus vancomycin.
Placencia FX; Kong L; Weisman LE
Pediatr Res; 2009 Apr; 65(4):420-4. PubMed ID: 19127212
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of recombinant lysostaphin-antibiotic combinations toward methicillin-resistant Staphylococcus aureus.
Polak J; Della Latta P; Blackburn P
Diagn Microbiol Infect Dis; 1993; 17(4):265-70. PubMed ID: 8112040
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of vancomycin and daptomycin against Staphylococcus aureus isolates collected over 29 years.
Appleman MD; Citron DM
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):441-4. PubMed ID: 20226335
[TBL] [Abstract][Full Text] [Related]
13. Antimicrobial susceptibility of Gram-positive bacterial isolates from the Asia-Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin, and teicoplanin: a SENTRY Program Report (2003-2004).
Biedenbach DJ; Bell JM; Sader HS; Fritsche TR; Jones RN; Turnidge JD
Int J Antimicrob Agents; 2007 Aug; 30(2):143-9. PubMed ID: 17531446
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.
Alós JI; García-Cañas A; García-Hierro P; Rodríguez-Salvanés F
J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of activity of recombinant lysostaphin against isolates of meticillin-resistant Staphylococcus aureus from Indian hospitals.
Kumar A; Khan IA; Sharma PR; K S; Ella KM
J Med Microbiol; 2014 May; 63(Pt 5):763-766. PubMed ID: 24623634
[No Abstract] [Full Text] [Related]
16. In vivo efficacy of the antimicrobial peptide ranalexin in combination with the endopeptidase lysostaphin against wound and systemic meticillin-resistant Staphylococcus aureus (MRSA) infections.
Desbois AP; Gemmell CG; Coote PJ
Int J Antimicrob Agents; 2010 Jun; 35(6):559-65. PubMed ID: 20206480
[TBL] [Abstract][Full Text] [Related]
17. Iodine-lithium-alpha-dextrin (ILαD) against Staphylococcus aureus skin infections: a comparative study of in-vitro bactericidal activity and cytotoxicity between ILαD and povidone-iodine.
Zisi AP; Exindari MK; Siska EK; Koliakos GG
J Hosp Infect; 2018 Feb; 98(2):134-140. PubMed ID: 28736269
[TBL] [Abstract][Full Text] [Related]
18. Emergence of vancomycin resistant Staphylococcus aureus (VRSA) from a tertiary care hospital from northern part of India.
Tiwari HK; Sen MR
BMC Infect Dis; 2006 Oct; 6():156. PubMed ID: 17067393
[TBL] [Abstract][Full Text] [Related]
19. Bactericidal activity of bacteriophage endolysin HY-133 against Staphylococcus aureus in comparison to other antibiotics as determined by minimum bactericidal concentrations and time-kill analysis.
Knaack D; Idelevich EA; Schleimer N; Molinaro S; Kriegeskorte A; Peters G; Becker K
Diagn Microbiol Infect Dis; 2019 Apr; 93(4):362-368. PubMed ID: 30554844
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activities of echinomycin against clinical isolates of Staphylococcus aureus.
Park YS; Shin WS; Kim SK
J Antimicrob Chemother; 2008 Jan; 61(1):163-8. PubMed ID: 17967852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
